Gastritis refers to the inflammation or irritation of the lining of the stomach. It can be caused due to various reasons including infection with Helicobacter pylori bacteria, excessive consumption of alcohol, usage of certain medications such as NSAIDs, and acid reflux. The key symptoms of gastritis include abdominal pain or discomfort, nausea, vomiting, and loss of appetite. Treatment options for gastritis include lifestyle modifications, medications such as proton pump inhibitors, H2 blockers, and antibiotics. The global gastritis treatment market is primarily driven by the increasing cases of gastritis worldwide coupled with the availability of various drugs and therapies for treating it.

The global gastritis treatment market is estimated to be valued at US$ 131.76 Bn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030. Factors such as rising prevalence of gastric infections and ulcers caused by H. pylori infection and increasing consumption of NSAIDs for pain management are boosting the market growth. Moreover, growing alcoholic beverage consumption leading to alcohol-induced gastritis is also propelling the demand for effective gastritis treatment drugs and medications.

Key Takeaways

Key players operating in the gastritis treatment market are Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Novartis AG, Takeda Pharmaceutical Company Limited. These players are focusing on developing innovative drug formulations and combination therapies to effectively treat different types of gastritis.

There exists massive opportunities for market players in the developing regions owing to growing healthcare investment and rising economic standards. Emerging countries hold promising growth prospects for the gastritis treatment market.

Key players are expanding their geographical presence globally through strategic collaborations and partnerships with regional pharmaceutical distributors. Companies are also undertaking mergers and acquisitions to strengthen their product portfolios and market share worldwide.

Market Drivers:

- Growing Prevalence of H. pylori Infection: H. pylori bacterial infection is the primary cause of chronic gastritis and peptic ulcers. According to the WHO, over 50% of the world's population is infected with H. pylori. This high prevalence of infection is a major driver of the gastritis treatment market.

- Increasing Usage of NSAIDs for Pain Management: Long term usage of NSAIDs for treating conditions like arthritis can damage the stomach lining and lead to drug-induced gastritis. As NSAID consumption rises across regions, the requirement for gastritis treatment is also augmenting significantly.

Market Restraints:

- Preference for Alternative Treatment Methods: Alternative treatment methods like probiotics, herbal medicines and dietary modifications are gaining popularity for managing gastritis symptoms. This could hinder the revenue growth of pharmaceutical drug manufacturers to some extent.

- Risk of Drug Resistance: Frequent and incorrect usage of antibiotics for H. pylori eradication can lead to development of drug resistance over time. This challenges the long term efficacy of antibiotic-based gastritis therapies.

Segment Analysis
The gastritis treatment market is segmented based on drug class, distribution channel, and region. By drug class, the proton pump inhibitors sub segment dominates as they provide effective relief from acidity and heartburn caused due to gastritis. Proton pump inhibitors are prescribed as the primary line of treatment for gastritis and have a well established market for long term usage. By distribution channel, hospital pharmacies hold a major share as many patients prefer consulting doctors for gastritis treatment and obtain medicine prescriptions from in-hospital pharmacies.

Global Analysis
Regionally, North America holds the largest share in the gastritis treatment market due to high awareness regarding disease diagnosis and treatment. Increased accessibility to healthcare facilities and favorable reimbursement policies also contribute to the dominant share. Asia Pacific is poised to grow at the fastest pace during the forecast period. This is attributed to rapidly improving healthcare infrastructure, increasing per capita healthcare expenditure, and rising geriatric population in major Asian countries like India and China.

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.

 

(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)